Updated clinical safety experience with fluvastatin

Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1993 • 28,274 citations

Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia

1987 • 3,889 citations

The Lipid Research Clinics Coronary Primary Prevention Trial Results

1984 • 2,673 citations

Regression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein B

1990 • 2,192 citations

Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin

1986 • 1,857 citations

Clofibrate and Niacin in Coronary Heart Disease

1975 • 1,660 citations

Beneficial Effects of Combined Colestipol-Niacin Therapy on Coronary Atherosclerosis and Coronary Venous Bypass Grafts

1987 • 1,651 citations

The Lipid Research Clinics Coronary Primary Prevention Trial Results

1984 • 1,373 citations

Regression of Coronary Atherosclerosis During Treatment of Familial Hypercholesterolemia With Combined Drug Regimens

1990 • 793 citations

Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study.

1984 • 685 citations

Beneficial Effects of Colestipol-Niacin on Coronary Atherosclerosis

1990 • 492 citations

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia

1991 • 489 citations

The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study.

1984 • 449 citations

Myopathy and Rhabdomyolysis Associated With Lovastatin-Gemfibrozil Combination Therapy

1990 • 422 citations

Expanded Clinical Evaluation of Lovastatin (EXCEL) Study Results

1991 • 343 citations

Efficacy and long-term adverse effect pattern of lovastatin

1988 • 338 citations

Rhabdomyolysis and Renal Injury With Lovastatin Use

1988 • 230 citations

Clinical Pharmacokinetics and Practical Applications of Simvastatin

1993 • 182 citations

Therapeutic response to lovasatain (Mevinolin) in nonfamilial hypercholesterolemia - A Multicenter study

1986 • 175 citations

Therapeutic Response to Lovastatin (Mevinolin) in Nonfamilial Hypercholesterolemia

1986 • 160 citations

Pravastatin

1991 • 117 citations

HMG‐CoA Reductase Inhibitors: An Exciting Development in the Treatment of Hyperlipoproteinemia

1991 • 105 citations

Efficacy and safety of pravastatin in patients with primary hypercholesterolemia

1990 • 77 citations

A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin.

1993 • 72 citations

Adverse Effects of Hypolipidaemic Drugs

1987 • 70 citations

Effects of Simvastatin and Cholestyramine in Familial and Nonfamilial Hypercholesterolemia

1990 • 64 citations

Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia.

1989 • 61 citations

Fluvastatin long-term extension trial (FLUENT): Summary of efficacy and safety

1994 • 52 citations

Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: Comparative analysis with a fluvastatin-cholestyramine combination

1994 • 47 citations

HMG CoA Reductase Inhibitors

1988 • 30 citations

Long-term experience with pravastatin in clinical research trials.

1993 • 20 citations

Safety and efficacy of combined gemfibrozil-lovastatin therapy for primary dyslipoproteinemias.

1990 • 19 citations

Drugs affecting lipid metabolism

1994 • 7 citations

Clinical Experience with Fluvastatin, the First Synthetic HMG-CoA Reductase Inhibitor

1993 • 4 citations